Combination Therapy for Bladder Cancer
Bladder cancer remains one of the most prevalent and challenging malignancies, with a significant impact on patient outcomes worldwide. At Alfa Cytology, our dedicated team of biologists and oncology experts has been at the forefront of exploring innovative combination therapies to address this critical healthcare concern.
Introduction to Combination Therapy
Bladder cancer is the 9th most commonly diagnosed cancer globally, with an estimated 430,000 new cases and 150,000 deaths each year. While recent breakthroughs in immunotherapy and targeted therapies have brought new hope, the road to optimal treatment remains paved with challenges. Specifically, the low response rates and the emergence of drug resistance have prompted the scientific community to investigate combination strategies that can overcome these limitations.
Ongoing Clinical Trials of Novel Combination Therapies for Bladder Cancer
| Trial ID |
Eligibility |
Phase |
Combination Therapy |
| NCT01928394 |
Advanced or metastatic bladder cancer |
Phase l/ll |
Nivolumab and lpilimumab |
| NCT03084471 |
Advanced bladder cancer |
Phase lll |
Duralumab and Tremelimumab |
| NCTO3219775 |
Metastatic or advanced transitional cell carcinoma |
Phase ll |
Nivolumab and lpilimumab |
| NCT03036098 |
Unresectable or metastatic UC |
Phase lll |
Nivolumab, lpilimumab, Gemcitabine / Cisplatin / Carboplati |
| NCTO2516241 |
Unresectable stage lV UC |
Phase lll |
Duralumab and Tremelimumab |
| NCTO4223856 |
Advanced or metastatic UC |
Phase lll |
EV and Pembrolizumab |
| NCTO3519256 |
BCG unresponsive high-risk NMIBC |
Phase ll |
Nivolumab, BMS-986205 and BCG |
| NCTO2560636 |
Advanced bladder cancer |
Phase l |
Pembrolizumab and radiotherapy |
| NCTO2643303 |
Bladder cancer |
Phase l/ll |
Tremelimumab, Durvalumab and polyICLC |
| NCT03473743 |
Metastatic or adyanced UC |
Phase lb/ll |
Erdafitinib, Cetrelimab and Platinum |
Our Services
At Alfa Cytology, we offer a comprehensive suite of preclinical services to support the development of novel combination therapies for bladder cancer. We provide a wide range of services tailored to the development of combination therapies and beyond.
- Combination Immunochemotherapy
- Combination of Radiotherapy with Targeted Therapy
- Synergistic Ferroptosis-starvation Therapy
- Combination of Photodynamic Therapy (PDT) with Immunotherapy
- Combination of Sonodynamic Therapy (SDT) with Chemotherapy
- Combination Chemo-photodynamic Therapy
- Combination of Chemodynamic Therapy (CDT) with Photothermal Therapy (PTT)
- And More
Our services include but are not limited to:
Contact Us
To learn more about our groundbreaking work in combination therapy for bladder cancer or to explore potential collaboration opportunities, please don't hesitate to contact us at Alfa Cytology. Our team of experts is ready to engage in productive discussions and explore how we can work together to revolutionize the treatment landscape for this devastating disease.
Reference
- Peng M., Xiao D., and et al. Novel Combination Therapies for the Treatment of Bladder Cancer. Front. Oncol. 2021, 10: 539527.
For research use only. Not intended for any clinical use.
Related Services
